Trial Profile

High-dose peretinoin as adjunctive therapy in hepatitis C-positive patients with hepatocellular carcinoma following curative therapy (surgical resection or transcutaneous radiofrequency ablation).

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 20 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Nov 2011 New source identified and integrated: University Hospital Medical Information Network - Japan record UMIN000006728.
24 Jan 2011 Results from a subgroup analysis presented at the ASCO Gastrointestinal Cancers Symposium in January 2011 (abstract 165), and reported in a Kowa Pharmaceutical media release.
20 Jan 2011 Results of subanalysis to be presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2011, according to a Kowa media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com